• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Trupanion Inc.

    6/7/24 5:17:06 PM ET
    $TRUP
    Medical Specialities
    Health Care
    Get the next $TRUP alert in real time by email
    S-8 1 d823408ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 7, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Trupanion, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-0480694

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    6100 4th Avenue S, Suite 200

    Seattle, Washington 98108

    (855) 727-9079

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

    2024 Equity Incentive Plan

    (Full title of the plan)

    Darryl Rawlings

    Chief Executive Officer

    Trupanion, Inc.

    6100 4th Avenue S, Suite 200

    Seattle, Washington 98108

    (855) 727-9079

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

    Andrew Ledbetter

    DLA Piper LLP (US)

    701 Fifth Avenue, Suite 6900

    Seattle, WA 98104-7044

    Telephone: (206) 839-4800

    Facsimile: (206) 839-4801

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☑    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller Reporting Company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    On June 5, 2024, the stockholders of Trupanion, Inc. (the “Registrant”) approved the Registrant’s 2024 Equity Incentive Plan (the “2024 Incentive Plan”), pursuant to which the Registrant may issue up to a maximum of 3,563,285 shares of the Registrant’s Common Stock, par value $0.00001 per share (“Common Stock”). The purpose of this Registration Statement on Form S-8 (this “Registration Statement”) is to register the 3,563,285 shares of Common Stock that are authorized for issuance under the 2024 Incentive Plan.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of this Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    Trupanion, Inc. (“we” or “our”) incorporates by reference into this registration statement the following documents that we have previously filed with the Securities and Exchange Commission (the “SEC”) (all File No. 001-36537):

     

      •  

    Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 27, 2024 (the “2023 Form 10-K”);

     

      •  

    The information specifically incorporated by reference into our 2023 Form 10-K from our definitive proxy statement on Schedule 14A relating to our 2024 annual meeting of stockholders (other than information furnished rather than filed), which was filed with the SEC on April 26, 2024;

     

      •  

    Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024;

     

      •  

    Our Current Reports on Form 8-K filed with the SEC on April 4, 2024, May 2, 2024, and June 7, 2024 (except as to information furnished not filed); and

     

      •  

    Exhibit 4.1 to the 2023 Form 10-K, which updates the description of our Common Stock under our registration statement on Form 8-A we filed pursuant to Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”), and any other amendment or report we file with the SEC for the purpose of updating this description.

    We deem all documents that we file pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this registration statement and until the completion of the offering under this registration statement, to be incorporated by reference into this registration statement and a part of this registration statement from the date of the filing of the document. We deem any statement contained in or that we deem is incorporated by reference into this registration statement as modified or superseded for purposes of this registration statement to the extent that a statement contained in this registration statement or in any document we deem is incorporated by reference into this registration statement conflicts with, negates, modifies or supersedes that statement. Any statement that we so modify or supersede will not constitute a part of this registration statement, except as modified or superseded.

     

    Item 4.

    Description of Securities.

    Not applicable.


    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

     

    Item 6.

    Indemnification of Directors and Officers.

    Section 102(b)(7) of the General Corporation Law of the State of Delaware, or DGCL, permits a Delaware corporation to limit the personal liability of its directors in accordance with the provisions set forth therein. Our Certificate of Incorporation provides that the personal liability of our directors shall be limited to the fullest extent permitted by applicable law.

    Section 145 of the DGCL authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities including reimbursement for expenses incurred arising under the Securities Act. Our Bylaws permit indemnification of directors, officers, employees and other agents to the maximum extent permitted by Delaware law. In addition, we have entered into indemnity agreements with each of our executive officers and directors. We also maintain a directors and officers liability insurance policy.

    The foregoing may reduce the likelihood of derivative litigation against our directors and executive officers and may discourage or deter stockholders or management from suing directors or executive officers for breaches of their duty of care, even though such actions, if successful, might otherwise benefit the company and our stockholders.

     

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.

     

    Item 8

    Exhibits.

     

    Exhibit
    Number
            Incorporated by Reference    Filed/
    Furnished
    Herewith
       Exhibit Description    Form    File No.    Exhibit    Filing Date
      3.1    Amended and Restated Certificate of Incorporation of Trupanion, Inc.    8-K    001-36537    3.1    6/12/2023   
      3.2    Amended and Restated Bylaws of Trupanion, Inc.    8-K    001-36537    3.2    6/12/2023   
      4.2    Form of Common Stock Certificate    S-1    333-196814    4.1    6/16/2014   
      5.1    Opinion of DLA Piper LLP (US).                X
     23.1    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm                X
     23.2    Consent of DLA Piper LLP (US) (included in Exhibit 5.1)                X
     24.1    Power of Attorney (included on signature page)                X
     99.1    2024 Equity Incentive Plan and forms of stock option award agreement, restricted stock agreement and restricted stock unit award agreement thereunder                X
    107    Filing Fee Table                X


    Item 9.

    Undertakings.

    We hereby undertake:

    (a) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) to include any prospectus required by section 10(a)(3) of the Securities Act;

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; and

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those clauses is contained in reports filed with or furnished to the SEC by us pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

    (b) that for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

    (c) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    We hereby further undertake that, for purposes of determining any liability under the Securities Act, each filing of our annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by any of our directors, officers or controlling persons in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on June 7, 2024.

     

    TRUPANION, INC.
    BY:   /s/ Darryl Rawlings
      Darryl Rawlings

     

     

    Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Darryl Rawlings, Fawwad Qureshi and Chris Kearns, and each of them, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Date: June 7, 2024       /s/ Darryl Rawlings
     

    Darryl Rawlings

    Chief Executive Officer and Chairperson of

    the Board of Directors

    (Principal Executive Officer)

    Date: June 7, 2024       /s/ Fawwad Qureshi
     

    Fawwad Qureshi

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    Date: June 7, 2024       /s/ Max Brodén
     

    Max Brodén

    Director

    Date: June 7, 2024       /s/ Jacqueline Davidson
     

    Jacqueline Davidson

    Director


    Date: June 7, 2024       /s/ Paulette Dodson
     

    Paulette Dodson

    Director

    Date: June 7, 2024       /s/ Murray Low
     

    Murray Low

    Director

    Date: June 7, 2024       /s/ Elizabeth McLaughlin
     

    Elizabeth McLaughlin

    Director

    Date: June 7, 2024       /s/ Howard Rubin
     

    Howard Rubin

    Director

    Date: June 7, 2024       /s/ Richard Enthoven
     

    Richard Enthoven

    Director

    Get the next $TRUP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRUP

    DatePrice TargetRatingAnalyst
    8/13/2025$47.00Neutral
    Cantor Fitzgerald
    1/23/2025$57.00Neutral → Overweight
    Piper Sandler
    7/19/2024Outperform
    William Blair
    5/16/2024$35.00 → $49.00Neutral → Buy
    BofA Securities
    5/8/2023$72.00 → $32.00Buy → Neutral
    BofA Securities
    9/21/2022$77.00Buy
    Jefferies
    8/4/2022$80.00 → $69.00Overweight → Neutral
    Piper Sandler
    2/24/2022$129.00 → $118.00Neutral → Buy
    B of A Securities
    More analyst ratings

    $TRUP
    SEC Filings

    View All

    SEC Form 144 filed by Trupanion Inc.

    144 - TRUPANION, INC. (0001371285) (Subject)

    12/29/25 4:01:33 PM ET
    $TRUP
    Medical Specialities
    Health Care

    SEC Form 144 filed by Trupanion Inc.

    144 - TRUPANION, INC. (0001371285) (Subject)

    12/19/25 4:06:40 PM ET
    $TRUP
    Medical Specialities
    Health Care

    SEC Form 144 filed by Trupanion Inc.

    144 - TRUPANION, INC. (0001371285) (Subject)

    11/25/25 4:01:35 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rawlings Darryl bought $499,663 worth of shares (20,700 units at $24.14), increasing direct ownership by 3% to 614,842 units (SEC Form 4) (Amendment)

    4/A - TRUPANION, INC. (0001371285) (Issuer)

    5/15/24 7:27:19 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Rawlings Darryl bought $499,663 worth of shares (20,700 units at $24.14), increasing direct ownership by 3% to 614,842 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    5/9/24 6:40:58 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    25 Years of Paws and Protection: Trupanion Reflects on a Quarter-Century of Protecting Our Furry Best Friends

    From Canada to the U.S. and now Continental Europe, Trupanion has helped more than 3.8 million pet parents budget for the unexpected. SEATTLE, Jan. 27, 2026 /PRNewswire/ -- Trupanion, Inc. (NASDAQ:TRUP), the leading provider of pet medical insurance in North America, is celebrating its 25th anniversary - a milestone that reflects a legacy of transforming how pet parents around the world approach care for their four-legged family members. Over the past 25 years, Trupanion has evolved from a visionary startup into a global leader protecting more than one million pets today. As t

    1/27/26 11:30:00 AM ET
    $TRUP
    Medical Specialities
    Health Care

    Trupanion Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leader in medical insurance for cats and dogs, announced today it will report financial results for its 2025 fourth quarter and full year after the market closes on Thursday, February 12, 2026. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET. A live webcast discussing results, guidance and management observations will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. A slide presentation will also be available on the site. P

    1/22/26 4:16:00 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Trupanion Named One of Seattle's Best Places to Work for the 7th Year in a Row

    SEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Trupanion, a leading provider of pet medical insurance, announced today they have been named one of Seattle's Best Places to Work for the seventh year in a row. Built In recognized Trupanion's industry leading work culture and employee benefits with two awards: one for Best Places to Work in Seattle and another for Best Large Places to Work in Seattle. "At Trupanion we are dedicated to creating a work culture that empowers our team, so it's an honor to be named one of Seattle's best companies for the seventh year in a row," said Trupanion CEO and President Margi Tooth. "Our mission is to protect pets, and the best way to live that mission to the

    1/8/26 12:15:00 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Gallagher John R sold $13,618 worth of shares (430 units at $31.67), decreasing direct ownership by 1% to 31,861 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    1/29/26 6:57:35 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Director Low Murray B exercised 23,213 shares at a strike of $8.57, increasing direct ownership by 18% to 154,534 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    1/12/26 8:44:15 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Chief Operating Officer Gallagher John R sold $16,146 worth of shares (430 units at $37.55), decreasing direct ownership by 1% to 32,291 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    12/30/25 8:52:54 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Trupanion with a new price target

    Cantor Fitzgerald initiated coverage of Trupanion with a rating of Neutral and set a new price target of $47.00

    8/13/25 8:15:02 AM ET
    $TRUP
    Medical Specialities
    Health Care

    Trupanion upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Trupanion from Neutral to Overweight and set a new price target of $57.00

    1/23/25 7:55:01 AM ET
    $TRUP
    Medical Specialities
    Health Care

    William Blair initiated coverage on Trupanion

    William Blair initiated coverage of Trupanion with a rating of Outperform

    7/19/24 7:44:19 AM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trupanion Inc.

    SC 13G/A - TRUPANION, INC. (0001371285) (Subject)

    11/8/24 10:46:38 AM ET
    $TRUP
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Trupanion Inc. (Amendment)

    SC 13G/A - TRUPANION, INC. (0001371285) (Subject)

    4/5/24 4:09:50 PM ET
    $TRUP
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Trupanion Inc. (Amendment)

    SC 13G/A - TRUPANION, INC. (0001371285) (Subject)

    2/12/24 11:02:49 AM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Leadership Updates

    Live Leadership Updates

    View All

    Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors

    Cohen to serve as Chair of the Audit Committee Grindr Inc. (NYSE:GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (NASDAQ:Z) and Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Of

    6/3/25 4:05:00 PM ET
    $ADPT
    $GRND
    $TRUP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Trupanion Partners with Leading Pet and Public Health Authorities to Launch Pet & Public Health Early Warning and Detection System

    Boehringer Ingelheim, Mars Science & Diagnostics and leading pet, public health and animal health authorities to join Advisory Board Collaboration to address emerging pet and public health threats to protect pets and peopleEarly detection potential has global pet and public health benefits  SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), the leading provider of medical insurance for cats and dogs in North America, in partnership with the Centers for Disease Control and Prevention (CDC), and leading pet industry partners, today announced the formation of a collaborative Advisory Board to launch a Pet & Public Health Early Warning & Detection System. The Advisory B

    8/14/24 9:00:00 AM ET
    $TRUP
    Medical Specialities
    Health Care

    Trupanion's Margi Tooth Appointed Chief Executive Officer Effective August 1, 2024

    SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leading provider of medical insurance for cats and dogs, today announced that its Board of Directors has unanimously approved the appointment of Margi Tooth to Chief Executive Officer, effective August 1, 2024. Tooth's appointment to CEO marks the culmination of a multi-year, board-led process. Tooth will also continue as President and hold the dual titles of CEO and President. Additionally, Tooth is anticipated to be appointed to Trupanion's Board of Directors during its July meeting. Trupanion's founder and outgoing CEO Darryl Rawlings will continue to serve in the role of Chair of the Board, in which capacity he

    5/2/24 4:04:29 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $TRUP
    Financials

    Live finance-specific insights

    View All

    Trupanion Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leader in medical insurance for cats and dogs, announced today it will report financial results for its 2025 fourth quarter and full year after the market closes on Thursday, February 12, 2026. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET. A live webcast discussing results, guidance and management observations will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. A slide presentation will also be available on the site. P

    1/22/26 4:16:00 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility

    SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the third quarter ended September 30, 2025. "We delivered record quarterly profitability while accelerating subscription pet growth for the third consecutive quarter," said Margi Tooth, Chief Executive Officer and President of Trupanion. "With a strong financial foundation, we have the flexibility to invest where it matters most - driving sustainable growth and expanding access to care. Our disciplined model continues to generate meaningful cash flow, positioning us to build on this momentum in the quarters ahead." Th

    11/6/25 4:05:00 PM ET
    $PNC
    $TRUP
    Major Banks
    Finance
    Medical Specialities
    Health Care

    Trupanion Announces Third Quarter 2025 Earnings Release and Conference Call

    SEATTLE, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leader in medical insurance for cats and dogs, announced today it will report financial results for its 2025 third quarter after the market closes on Thursday, November 6, 2025. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET. A live webcast discussing results, guidance and management observations will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. A slide presentation will also be available on the site. Participants can

    10/21/25 4:15:24 PM ET
    $TRUP
    Medical Specialities
    Health Care